Many studies showed that O6-methylguanin DNA methyltransferase (MGMT) promoter methylation serves as a prognostic factor for progression-free survival (PFS) and overall survival (OS) associated with a positive response to alkylating agents, such as TMZ, in newly diagnosed GBM patients [5,6,7,8,9,10]. Here, MGMT is linked to glioblastoma.